

Special Issue

Genetic Testing for Cancer Susceptibility

Message from the Guest Editors

Research advances combined with improvements in technologies are deeply modifying the knowledges of cancer susceptibility, generating, simultaneously, news and unexpected scenarios. Different challenges are now represented by the evidence of overlapping genetic syndromes, findings of incidental variants, and difficulties in correlations between variants and interpretations. These have a large impact on risk estimate, prognosis, and tailored therapies outcomes. This Special Issue arises from the need for meaningful risk data on genetic susceptibility obtained by cutting-edge research to improve the clinical interpretation of germline multi-gene panel testing. Research articles, reviews, as well as short communications are invited to submit to this Special Issue.

Guest Editors

Dr. Francesco Baudi

Department of Health Science, Magna Graecia University of Catanzaro, Catanzaro, Italy

Dr. Rodolfo Iuliano

Department of Health Sciences, Campus S. Venuta, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy

Deadline for manuscript submissions

closed (10 November 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/175391

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))